Latest Breaking News On - தைரோகேர் தொழில்நுட்பங்கள் - Page 2 : vimarsana.com

The representation is being given by South Chemists & Distributors Association (SCDA) which says that the proposed acquisition needs to be rejected by the CCI Allowing PharmEasy to acquire Thyrocare which has a wide presence in the diagnostics market would give the company an unfair advantage, said the SCDA Besides calling epharmacies illegal, the SCDA also claimed that the only reason for the adoption of epharmacies is that they offer discounts Healthtech unicorn PharmEasy’s proposed acquisition of Thyrocare, which is subject to regulatory approval, is likely to face a legal challenge at the Competition Commission of India (CCI) from a group of chemists and druggists. The representation is being given by South Chemists & Distributors Association (SCDA) which says PharmEasy’s proposed acquisition of Thyrocare Technologies needs to be rejected by the CCI.

Mumbai bhabha atomic research centreCompetition commission of indiaTata groupChemists distributors associationCompetition commissionSouth chemistsDistributors associationThyrocare technologiesBhabha atomic research centreபோட்டி தரகு ஆஃப் இந்தியாடாடா குழுவேதியியலாளர்கள் விநியோகஸ்தர்கள் சங்கம்போட்டி தரகுதெற்கு வேதியியலாளர்கள்விநியோகஸ்தர்கள் சங்கம்தைரோகேர் தொழில்நுட்பங்கள்